Predictive Oncology Performance
| POAIDelisted Stock | USD 5.95 0.00 0.00% |
The company holds a Beta of -5.28, which implies a somewhat significant risk relative to the market. As returns on the market increase, returns on owning Predictive Oncology are expected to decrease by larger amounts. On the other hand, during market turmoil, Predictive Oncology is expected to outperform it. At this point, Predictive Oncology has a negative expected return of -0.42%. Please make sure to check Predictive Oncology's skewness, and the relationship between the total risk alpha and day median price , to decide if Predictive Oncology performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Weakest
Weak | Strong |
Over the last 90 days Predictive Oncology has generated negative risk-adjusted returns adding no value to investors with long positions. Despite weak performance in the last few months, the Stock's basic indicators remain fairly strong which may send shares a bit higher in March 2026. The recent confusion may also be a sign of long-lasting up-swing for the firm traders. ...more
| Begin Period Cash Flow | 8.7 M | |
| Total Cashflows From Investing Activities | 22.5 K |
Predictive |
Predictive Oncology Relative Risk vs. Return Landscape
If you would invest 721.00 in Predictive Oncology on November 4, 2025 and sell it today you would lose (126.00) from holding Predictive Oncology or give up 17.48% of portfolio value over 90 days. Predictive Oncology is currently does not generate positive expected returns and assumes 7.2462% risk (volatility on return distribution) over the 90 days horizon. In different words, 65% of stocks are less volatile than Predictive, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Predictive Oncology Target Price Odds to finish over Current Price
The tendency of Predictive Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move above the current price in 90 days |
| 5.95 | 90 days | 5.95 | about 84.13 |
Based on a normal probability distribution, the odds of Predictive Oncology to move above the current price in 90 days from now is about 84.13 (This Predictive Oncology probability density function shows the probability of Predictive Stock to fall within a particular range of prices over 90 days) .
Given the investment horizon of 90 days Predictive Oncology has a beta of -5.28 indicating as returns on its benchmark rise, returns on holding Predictive Oncology are expected to decrease by similarly larger amounts. On the other hand, during market turmoils, Predictive Oncology is expected to outperform its benchmark. Additionally Predictive Oncology has a negative alpha, implying that the risk taken by holding this instrument is not justified. The company is significantly underperforming the Dow Jones Industrial. Predictive Oncology Price Density |
| Price |
Predictive Modules for Predictive Oncology
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Predictive Oncology. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Predictive Oncology Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Predictive Oncology is not an exception. The market had few large corrections towards the Predictive Oncology's value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Predictive Oncology, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Predictive Oncology within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | -0.64 | |
β | Beta against Dow Jones | -5.28 | |
σ | Overall volatility | 4.08 | |
Ir | Information ratio | -0.08 |
Predictive Oncology Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Predictive Oncology for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Predictive Oncology can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Predictive Oncology is now traded under the symbol AGPU. Please update your portfolios or report it if you believe this is an error. Report It! | |
| Predictive Oncology is not yet fully synchronised with the market data | |
| Predictive Oncology generated a negative expected return over the last 90 days | |
| Predictive Oncology has high historical volatility and very poor performance | |
| Predictive Oncology has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 1.62 M. Net Loss for the year was (10.86 M) with profit before overhead, payroll, taxes, and interest of 814.04 K. | |
| Predictive Oncology currently holds about 25.39 M in cash with (11.96 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.32. | |
| Latest headline from news.google.com: Kazia Therapeutics Sees New Option Listings - GuruFocus |
Predictive Oncology Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Predictive Stock often depends not only on the future outlook of the current and potential Predictive Oncology's investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Predictive Oncology's indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 5.5 M | |
| Cash And Short Term Investments | 734.7 K |
Predictive Oncology Fundamentals Growth
Predictive Stock prices reflect investors' perceptions of the future prospects and financial health of Predictive Oncology, and Predictive Oncology fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Predictive Stock performance.
| Return On Equity | -7.46 | |||
| Return On Asset | -1.29 | |||
| Operating Margin | (906.54) % | |||
| Current Valuation | 21.66 M | |||
| Shares Outstanding | 3.39 M | |||
| Price To Book | 1.43 X | |||
| Price To Sales | 12.07 X | |||
| Revenue | 1.62 M | |||
| EBITDA | (10.24 M) | |||
| Cash And Equivalents | 25.39 M | |||
| Cash Per Share | 0.32 X | |||
| Total Debt | 2.13 M | |||
| Debt To Equity | 0.01 % | |||
| Book Value Per Share | (100.94) X | |||
| Cash Flow From Operations | (11.96 M) | |||
| Earnings Per Share | (141.32) X | |||
| Total Asset | 4.97 M | |||
| Retained Earnings | (180.43 M) | |||
About Predictive Oncology Performance
By evaluating Predictive Oncology's fundamental ratios, stakeholders can gain valuable insights into Predictive Oncology's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Predictive Oncology has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Predictive Oncology has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
Predictive Oncology Inc., a knowledge-driven company, focuses on developing personalized cancer therapies using artificial intelligence primarily in the United States. Predictive Oncology Inc. was incorporated in 2002 and is based in Eagan, Minnesota. Predictive Oncology operates under Medical Instruments Supplies classification in the United States and is traded on NASDAQ Exchange. It employs 30 people.Things to note about Predictive Oncology performance evaluation
Checking the ongoing alerts about Predictive Oncology for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Predictive Oncology help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Predictive Oncology is now traded under the symbol AGPU. Please update your portfolios or report it if you believe this is an error. Report It! | |
| Predictive Oncology is not yet fully synchronised with the market data | |
| Predictive Oncology generated a negative expected return over the last 90 days | |
| Predictive Oncology has high historical volatility and very poor performance | |
| Predictive Oncology has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 1.62 M. Net Loss for the year was (10.86 M) with profit before overhead, payroll, taxes, and interest of 814.04 K. | |
| Predictive Oncology currently holds about 25.39 M in cash with (11.96 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.32. | |
| Latest headline from news.google.com: Kazia Therapeutics Sees New Option Listings - GuruFocus |
- Analyzing Predictive Oncology's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Predictive Oncology's stock is overvalued or undervalued compared to its peers.
- Examining Predictive Oncology's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Predictive Oncology's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Predictive Oncology's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Predictive Oncology's stock. These opinions can provide insight into Predictive Oncology's potential for growth and whether the stock is currently undervalued or overvalued.
Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation. You can also try the CEOs Directory module to screen CEOs from public companies around the world.
Other Consideration for investing in Predictive Stock
If you are still planning to invest in Predictive Oncology check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Predictive Oncology's history and understand the potential risks before investing.
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments |